Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
433.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 2.50 (0.58%)
Market Cap: £212.96m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Interim Management Statement

26 Oct 2012 07:00

RNS Number : 5898P
Zotefoams PLC
26 October 2012
 



26 October 2012

 

Zotefoams plc

("Zotefoams" or "the Company")

 

Interim Management Statement for the Quarter ended 30 September 2012

 

26 October 2012 - Zotefoams, which manufactures and sells high-performance foams, today announces its interim management statement for the third quarter ended 30 September 2012.

 

Third quarter Polyolefin foam sales increased by approximately 3% in constant currency compared to the same period last year. Sales growth in North America and Rest of World was around 6% while we experienced more modest growth in UK and Continental Europe. The impact of a weaker euro reduced the sterling value of European sales by approximately 10% while there was a small positive impact on sales elsewhere from relative US dollar strength compared with the third quarter in 2011.

 

In the third quarter of 2011 there was high demand for our T-Tubes® insulation products and, due to timing of projects, comparative sales were much lower in 2012. As a result, revenue from our High-Performance Polymers ("HPP") segment was approximately 20% below the same period last year despite an increase in sales of our patented ZOTEK® F fluoropolymer foams. While sales in HPP have historically been subject to short term fluctuations, we remain confident of strong underlying growth in this segment, much of which is to the aviation market.

 

In July and August 2012 MuCell Extrusion LLC ("MEL"), which licenses foaming technology, made important advances within the film and sheet markets. Agreements with Dow Chemical and Styron to license-in their complementary patents have enhanced our ability to offer attractive licences in packaging technology, and activity and interest levels have increased as a direct result. The development pipeline of new projects continues to grow from a small base and in the medium term we expect good progress in conversion of additional signed MEL licences. Currently MEL is a developmental business which is cash generative and we are increasing investment commensurate with our expectations for growth over the coming years.

 

For the third quarter the euro-denominated price of low density polyethylene (LDPE), our main raw material, was at a similar average price compared to the same period last year.

 

The Company continues to progress, with a forward order book into early 2013. Although we are mindful of the uncertain economic environment and the potential for movements in exchange rates to have a translation impact on our reported results, the Board remains confident of a satisfactory outcome for the year and continued progress in the future.

 

 

Enquiries:

Zotefoams plc

0208-664-1600

David Stirling, Managing Director

Clifford Hurst, Finance Director

FTI Consulting

0207-831-3113

Ben Brewerton, John Dineen, Victoria Foster Mitchell

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular material technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces lightweight foams in Croydon, UK and Kentucky, USA for diverse markets worldwide through its global sales force. Zotefoams also owns and licenses patented MuCell® microcellular foam technology from a base in Massachusetts, USA to customers worldwide and sells T-Tubes® advanced insulation systems made from its patented ZOTEK® fluoropolymer foams.

 

www.zotefoams.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUVSBRUSARUAA
Date   Source Headline
12th Jul 202212:39 pmRNSDirector/PDMR Shareholding
8th Jul 20227:00 amRNSNotice of Results
30th Jun 20224:52 pmRNSDirector/PDMR Shareholding
8th Jun 20224:40 pmRNSSecond Price Monitoring Extn
8th Jun 20224:35 pmRNSPrice Monitoring Extension
8th Jun 20228:49 amRNSDirector/PDMR Shareholding
26th May 20224:41 pmRNSSecond Price Monitoring Extn
26th May 20224:36 pmRNSPrice Monitoring Extension
25th May 20221:04 pmRNSResult of the 2022 Annual General Meeting
25th May 20227:00 amRNSTrading Update
18th May 20224:41 pmRNSSecond Price Monitoring Extn
18th May 20224:36 pmRNSPrice Monitoring Extension
12th May 20223:58 pmRNSDirector/PDMR Shareholding
11th May 20222:13 pmRNSDirector/PDMR Shareholding
25th Apr 20225:16 pmRNSDirector/PDMR Shareholding
25th Apr 20227:00 amRNS2021 Annual Report and Notice of the 2022 AGM
11th Apr 20223:49 pmRNSDirector/PDMR Shareholding
22nd Mar 20227:00 amRNSPreliminary Results
14th Mar 202212:30 pmRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSNotice of results and investor presentation
15th Feb 20224:26 pmRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSFull Year Trading Update
12th Jan 202211:12 amRNSDirector/PDMR Shareholding
23rd Dec 20211:56 pmRNSDirector/PDMR Shareholding
17th Dec 20217:00 amRNSTrading Update
14th Dec 202111:55 amRNSDirector/PDMR Shareholding
12th Nov 202112:41 pmRNSDirector/PDMR Shareholding
10th Nov 20215:48 pmRNSHolding(s) in Company
4th Nov 20215:59 pmRNSHolding(s) in Company
4th Nov 20213:31 pmRNSDirector/PDMR Shareholding
3rd Nov 20217:00 amRNSQ3 Trading Update
15th Oct 202112:10 pmRNSDirector/PDMR Shareholding
12th Oct 202111:05 amRNSDirector/PDMR Shareholding
1st Oct 20213:31 pmRNSHolding(s) in Company
14th Sep 202110:05 amRNSDirector/PDMR Shareholding
12th Aug 20212:28 pmRNSDirector/PDMR Shareholding
10th Aug 20217:00 amRNSInterim Results
19th Jul 20219:26 amRNSNotice of Results
13th Jul 20211:59 pmRNSDirector/PDMR Shareholding
14th Jun 20213:06 pmRNSDirector/PDMR Shareholding
14th Jun 202111:35 amRNSDirector/PDMR Shareholding
10th Jun 20214:41 pmRNSDirector/PDMR Shareholding
9th Jun 20213:48 pmRNSDirector/PDMR Shareholding
2nd Jun 20213:49 pmRNSHolding(s) in Company
26th May 202112:08 pmRNSResult of AGM
26th May 20217:00 amRNSTrading Update
12th May 20213:44 pmRNSDirector/PDMR Shareholding
28th Apr 20212:05 pmRNSDirector/PDMR Shareholding
26th Apr 20213:16 pmRNS2020 Annual Report, Notice of the 2021 AGM
13th Apr 20212:06 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.